Preliminary Efficacy Data from Phase Ib/IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer presented at European Society for Medical Oncology (ESMO) CongressInitiates Stage 2 of the Phase IIa clinical trial of RX-3117 in Relapsed and Refractory Metastatic Pancreatic CancerBegins Enrollment in Phase Ib/IIa trial of RX-3117 in Advanced Bladder Cancer ROCKVILLE, Md., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2016 and provided an update on the Company's clinical development programs. "Rexahn achieved a major milestone in the third quarter with the progression of RX-3117 to stage 2 of a Phase Ib/IIa clinical trial evaluating RX-3117 in relapsed and refractory pancreatic cancer," said Peter D. Suzdak, Ph.D., Chief Executive Officer. "We are very encouraged by the stage 1 data which shows preliminary evidence of efficacy with the most difficult to treat patients who have not been responsive to multiple prior rounds of chemotherapy. Data from stage 1 of this clinical trial were recently presented at the European Society of Medical Oncology (ESMO) annual congress." "RX-3117 is also being evaluated in bladder cancer, another difficult to treat patient group. We commenced enrollment in a Phase Ib/IIa clinical trial of RX-3117 in patients with advanced bladder cancer, where there is a high unmet need for better medications and no major advance in treatments in the last twenty years," continued Dr. Suzdak. "During the third quarter, Rexahn continued to advance the Phase IIa clinical trial of Archexin ® in combination with everolimus in metastatic renal cell carcinoma. The study continues to show promising signs of clinical efficacy evidenced by both stable disease and a reduction in tumor burden in several patients," Dr. Suzdak added. "We are nearing completion of our Phase I dose escalating study with Supinoxin™ and anticipate beginning a Phase Ib/IIa study of Supinoxin in patients with triple negative breast cancer in the near future. Data from the Supinoxin Phase I study were recently presented at ESMO. The updated results show that Supinoxin is safe and well tolerated at the doses and dosing schedules tested with no dose limiting toxicities or treatment-related serious adverse events. Initial signs of clinical activity have been observed in patients with breast, neuroendocrine, paraganglioma, head and neck and colorectal cancers, demonstrating stable disease for up to 880 days. Of these patients approximately 55% had received four or more therapies prior to their enrollment in the Phase I clinical study and we are encouraged to see signs of clinical activity in this study," concluded Dr. Suzdak.